Mesoblast (MESO) EBIT Margin Growth (5y) (2021 - 2023)

Mesoblast (MESO) EBIT Margin Growth (5y) (2021 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Mesoblast 19.81 Bn 19.68 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2023 356,667.00
Mar 31, 2023 323,037.00
Dec 31, 2022 115,595.00
Sep 30, 2022 181,343.00
Jun 30, 2022 139,835.00
Dec 31, 2021 564,766.00
Jun 30, 2021 -23,790.00